Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration in established Parkinson's models?¶
Notebook ID: nb-SDA-2026-04-26-gap-pubmed-20260410-145520-5692b02e-debate · Analysis: SDA-2026-04-26-gap-pubmed-20260410-145520-5692b02e-debate
Domain: neurodegeneration · Date: 2026-04-25
Research Question¶
While RGS6 deficiency causes Parkinson's-like pathology, whether enhancing RGS6 function or targeting the D2R-Gi/o pathway can reverse or prevent established neurodegeneration remains untested. This is crucial for therapeutic development.
Gap type: open_question Source paper: Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice. (2019, JCI Insight, PMID:31120439)
Debate Summary¶
Debate transcript not available for this analysis.
Hypotheses Ranked by Composite Score¶
Total hypotheses: 5
| Title | Composite | Confidence | Novelty | Feasibility | Impact |
|---|---|---|---|---|---|
| AAV-mediated RGS6 re-expression in SNpc after pathology onset | 0.53 | 0.42 | 0.74 | 0.58 | 0.55 |
| TH-neuron-restricted RGS6 rescue to test cell-autonomous therapeutic sufficiency | 0.46 | 0.36 | 0.68 | 0.44 | 0.47 |
| Pharmacologic modulation of D2 autoreceptor-Gi/o signaling in established PD mod | 0.42 | 0.29 | 0.51 | 0.61 | 0.34 |
| Combination RGS6 restoration plus D2-pathway modulation | 0.31 | 0.18 | 0.62 | 0.33 | 0.29 |
| RGS6 isoform switching or small-molecule RGS6 activation as disease-modifying th | 0.22 | 0.08 | 0.71 | 0.12 | 0.18 |
Knowledge Graph Edges¶
No KG edges found for this analysis.
Key Citations¶
No citations found for this analysis.